Literature DB >> 22777614

Factors predisposing metastatic tumor antigen 1 overexpression in hepatitis B virus associated hepatocellular carcinoma.

Young-Joo Jin1, Young-Hwa Chung, Jeong A Kim, Won Hyung Park, Danbi Lee, Dong Dae Seo, Soo Hyung Ryu, Myoung Kuk Jang, Eunsil Yu, Young Joo Lee.   

Abstract

BACKGROUND/AIM: Overexpression of metastatic tumor antigen-1 (MTA-1) is suggested to be associated with frequent postoperative recurrence and poor survival of hepatocellular carcinoma (HCC) patients. In this study, we intended to determine clinical factors predisposing the overexpression of MTA-1 in patients with hepatitis B virus (HBV)-associated HCC and also examine whether MTA-1 overexpression affects the survival periods of these patients treated with curative surgical resection.
METHODS: A total of 303 patients with HBV-associated HCC who underwent curative surgical resection were subjected. The expressions of MTA-1 in HCC and surrounding non-tumor liver tissues were evaluated using the immunohistochemical method. The clinical, radiological and histological characteristics of the patients were analyzed in relation to the expression of MTA-1 to find predisposing factors of MTA-1 overexpression.
RESULTS: MTA-1 was overexpressed in 104 HCC tissues (34.3 %) and none of the surrounding non-tumor tissues. Clinically, MTA-1 overexpression was significantly associated with younger age, female gender, higher serum alpha-fetoprotein level, and Child-Turcotte-Pugh class A. Also, portal vein thrombosis, microvascular invasion, capsular invasion and poorly histological differentiation were associated with overexpression of MTA-1. The cumulative survival rates were significantly lower in patients with MTA-1 overexpression compared with those in the MTA-1 negative group (P = 0.03). In addition to the overexpression of MTA-1, the presence of microvascular or capsular invasion was a significant factor determining the poor survival of the patients with HBV-associated HCC after curative resection.
CONCLUSIONS: MTA-1 is overexpressed in patients with HBV-associated HCC of invasive nature. MTA-1 overexpression is associated with shorter survival periods of patients with HBV-associated HCC after curative resection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22777614     DOI: 10.1007/s10620-012-2296-z

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  33 in total

Review 1.  Prognostic prediction and treatment strategy in hepatocellular carcinoma.

Authors:  Jordi Bruix; Josep M Llovet
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

2.  Resection of hepatocellular carcinoma: the effect of surgical margin and blood transfusion on long-term survival. Analysis of 209 consecutive patients.

Authors:  J G Tralhão; S Kayal; I Dagher; M Sanhueza; C Vons; D Franco
Journal:  Hepatogastroenterology       Date:  2007-06

3.  Expression of the MTA1 mRNA in advanced lung cancer.

Authors:  Hidefumi Sasaki; Satoru Moriyama; Yoshiaki Nakashima; Yoshihiro Kobayashi; Haruhiro Yukiue; Masahiro Kaji; Ichiro Fukai; Masanobu Kiriyama; Yosuke Yamakawa; Yoshitaka Fujii
Journal:  Lung Cancer       Date:  2002-02       Impact factor: 5.705

4.  Do young hepatocellular carcinoma patients have worse prognosis? The paradox of age as a prognostic factor in the survival of hepatocellular carcinoma patients.

Authors:  Chien-Hung Chen; Ting-Tsung Chang; Ken-Sheng Cheng; Wei-Wen Su; Sheng-Shun Yang; Hans Hsienhong Lin; Shun-Sheng Wu; Chuan-Mo Lee; Chi-Sin Changchien; Chien-Jen Chen; Jin-Chuan Sheu; Ding-Shinn Chen; Sheng-Nan Lu
Journal:  Liver Int       Date:  2006-09       Impact factor: 5.828

5.  Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases.

Authors:  K Yuki; S Hirohashi; M Sakamoto; T Kanai; Y Shimosato
Journal:  Cancer       Date:  1990-11-15       Impact factor: 6.860

6.  Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival.

Authors:  E Villa; A Moles; I Ferretti; P Buttafoco; A Grottola; M Del Buono; M De Santis; F Manenti
Journal:  Hepatology       Date:  2000-08       Impact factor: 17.425

7.  Overexpression of metastatic tumor antigen 1 in hepatocellular carcinoma: Relationship to vascular invasion and estrogen receptor-alpha.

Authors:  Woo Sung Moon; Kenneth Chang; Andrzej S Tarnawski
Journal:  Hum Pathol       Date:  2004-04       Impact factor: 3.466

8.  Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure.

Authors:  J Bruix; A Castells; J Bosch; F Feu; J Fuster; J C Garcia-Pagan; J Visa; C Bru; J Rodés
Journal:  Gastroenterology       Date:  1996-10       Impact factor: 22.682

9.  Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma.

Authors:  Takeaki Ishizawa; Kiyoshi Hasegawa; Taku Aoki; Michiro Takahashi; Yosuke Inoue; Keiji Sano; Hiroshi Imamura; Yasuhiko Sugawara; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  Gastroenterology       Date:  2008-03-08       Impact factor: 22.682

Review 10.  Emerging roles of MTA family members in human cancers.

Authors:  Rakesh Kumar; Rui-An Wang; Rozita Bagheri-Yarmand
Journal:  Semin Oncol       Date:  2003-10       Impact factor: 4.929

View more
  12 in total

Review 1.  Molecular targeted therapy for hepatocellular carcinoma: current and future.

Authors:  Jung Woo Shin; Young-Hwa Chung
Journal:  World J Gastroenterol       Date:  2013-10-07       Impact factor: 5.742

Review 2.  Molecular mechanisms of gender disparity in hepatitis B virus-associated hepatocellular carcinoma.

Authors:  Wei-Cheng Liu; Quan-Yan Liu
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

3.  Metastasis-associated protein 1 as a new prognostic marker for solid tumors: a meta-analysis of cohort studies.

Authors:  Haiqing Luo; Hongjiao Li; Na Yao; Liren Hu; Taiping He
Journal:  Tumour Biol       Date:  2014-03-06

4.  TLR3 Plays Significant Roles against HBV-Associated HCC.

Authors:  Xiao-Lan Chen; Yu-Yin Xu; Li Chen; Gui-Lan Wang; Yin Shen
Journal:  Gastroenterol Res Pract       Date:  2015-04-23       Impact factor: 2.260

5.  Role of metastasis-associated protein 1 in prognosis of patients with digestive tract cancers: A meta-analysis.

Authors:  Guo-Dong Cao; Bo Chen; Mao-Ming Xiong
Journal:  PLoS One       Date:  2017-06-01       Impact factor: 3.240

6.  Characterization of metastatic tumor antigen 1 and its interaction with hepatitis B virus X protein in NF-κB signaling and tumor progression in a woodchuck hepatocellular carcinoma model.

Authors:  Yung-Tsung Li; Chun-Jen Liu; Tung-Hung Su; Huei-Ru Cheng; Yung-Ming Jeng; Hsiu-Lin Lin; Chih-Chiang Wang; Jia-Horng Kao; Pei-Jer Chen; Ding-Shinn Chen; Hui-Lin Wu
Journal:  Oncotarget       Date:  2016-07-26

Review 7.  ARD1/NAA10 in hepatocellular carcinoma: pathways and clinical implications.

Authors:  Danbi Lee; Myoung-Kuk Jang; Ji Hae Seo; Soo Hyung Ryu; Jeong A Kim; Young-Hwa Chung
Journal:  Exp Mol Med       Date:  2018-07-27       Impact factor: 8.718

Review 8.  Role of Sex Hormones in the Development and Progression of Hepatitis B Virus-Associated Hepatocellular Carcinoma.

Authors:  Maurizio Montella; Giovanni D'Arena; Anna Crispo; Mario Capunzo; Flavia Nocerino; Maria Grimaldi; Antonio Barbieri; Anna Maria D'Ursi; Mario Felice Tecce; Alfonso Amore; Massimiliano Galdiero; Gennaro Ciliberto; Aldo Giudice
Journal:  Int J Endocrinol       Date:  2015-09-27       Impact factor: 3.257

9.  Inhibition of MTA1 by ERα contributes to protection hepatocellular carcinoma from tumor proliferation and metastasis.

Authors:  Lei Deng; Hui Yang; Junwei Tang; Zhe Lin; Aihong Yin; Yun Gao; Xuehao Wang; Runqiu Jiang; Beicheng Sun
Journal:  J Exp Clin Cancer Res       Date:  2015-10-26

10.  Evolutionary cancer-favoring engineered vaccinia virus for metastatic hepatocellular carcinoma.

Authors:  So Young Yoo; Su-Nam Jeong; Dae Hwan Kang; Jeong Heo
Journal:  Oncotarget       Date:  2017-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.